The Amplatzer Piccolo Occluder is designed to treat patent ductus arteriosus. Credit: Abbott.

Abbott has reported positive three-year data from the ADO II AS trial of its Amplatzer Piccolo Occluder.

The findings from the trial demonstrated the Amplatzer Piccolo device’s effectiveness and safety in closing a potentially life-threatening hole in the heart, known as a patent ductus arteriosus (PDA), in new-born babies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A self-expanding, wire mesh device, Amplatzer Piccolo is inserted through a small incision in the leg and guided to the heart through vessels, before being placed to close the PDA.

According to the company, the device is the first and only minimally invasive transcatheter treatment in the world that is approved for sealing a PDA in premature babies with the congenital heart defect.

Abbott structural heart business senior vice-president Michael Dale said: “There are thousands of stories of infants in need that inspire us to continue innovating to help the youngest and most vulnerable babies.

See Also:

“We realise just how important our commitment to restoring health is when we hear about paediatric patients who can begin living their best lives thanks to devices like our Amplatzer Piccolo Occluder.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the study, the Amplatzer Piccolo device showed a high survival rate of 95.5%, without any deaths related to the procedure and complete closure of PDA in almost all patients.

It also demonstrated a high implant success rate of 95.5%.

Additionally, the study found low device-related serious adverse event rates after the procedure.

An additional benefit of Amplatzer Piccolo is that its minimally invasive approach reduces the need for infants to undergo riskier surgical procedures.

Last month, Abbott’s Proclaim Plus spinal cord stimulation (SCS) system with FlexBurst360 therapy received US Food and Drug Administration (FDA) approval.